Fuad

...now browsing by category

 

Bad News Clouds Two Bio Defense Stocks

Friday, December 11th, 2009

Written by Staff and Wire Reports
Tuesday, 08 December 2009 01:28

Key news developments will affect shares of these two companies who help meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons.

The two companies which waited until late after hours on Monday to announce that the Biomedical Research and Development Authority had informed them of some negative news.

After hours on Monday, PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced that the Department of Health and Human Services Biomedical Research and Development Authority (BARDA) has canceled its request for proposal (RFP) for Recombinant Protective Antigen Anthrax Vaccine for the Strategic National Stockpile (RFP BARDA 08-15).

PharmAthene was informed of BARDA’s decision during a meeting late Monday afternoon with BARDA representatives.  BARDA issued a press release after the close of the securities markets announcing that it will cancel RFP BARDA 08-15 because it did not believe vaccine developers submitting proposals in response to the request for proposal (RFP) could have product ready for FDA licensure within 8 years.

In similar news…

Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has been advised by the Office of the Biomedical Advanced Research and Development Authority (BARDA) that the Request for Proposal (RFP) for the procurement of rPA vaccines has been cancelled in favor of a Broad Agency Announcement (BAA) for rPA vaccine development. According to BARDA officials, BARDA took this action after a technical evaluation panel determined that none of the vaccine developers submitting proposals could meet the Project BioShield statutory requirement of having a product ready for licensure within 8 years.

Simultaneously, BARDA issued an amendment to BAA 09-34 to enable companies to submit proposals to obtain development funding for rPA vaccine candidates. The due date for all proposals is February 1, 2010. During a meeting with company officials today, BARDA strongly encouraged Emergent to submit a proposal to this BAA. Emergent intends to submit its proposal by the end of this year.

While the decision by BARDA has no impact on the company’s $400 million procurement contract with the Centers for Disease Control and Prevention (CDC) for the manufacture and delivery of 14.5 million doses of BioThrax® into the Strategic National Stockpile (SNS). Investors are still likely to react negatively to the news.

After selling dies down, there may be a bounce trade opportunity for EBS followers since the company feels that “BioThrax remains a critical and long-term countermeasure for the US government,” said Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions. “In addition, based upon encouragement by the USG, we believe our rPA vaccine is well-positioned to obtain a development contract under this BAA. Our anthrax franchise solidifies Emergent as a leader in the development and supply of anthrax medical countermeasures.”

Source :: http://biomedreports.com/articles/most-popular/20870-bad-news-clouds-move-in-on-these-stocks.html

Reblog this post [with Zemanta]

Posted in BioThrax, Biotechnology, Chief executive officer, Department of Health and Human Services, Emergent BioSolutions Inc, Fuad, Fuad El-Hibri, U.S. Food and Drug Administration | No Responses »
Tags: , , , , , , ,

Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares

Friday, August 14th, 2009

CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.

EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s immune system to prevent or treat disease. Their products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Their marketed product BioThrax? (Anthrax Vaccine Adsorbed) is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent BioSolutions Inc. has a market cap of $511.8 million; its shares were traded at around $16.91 with a P/E ratio of 13.1 and P/S ratio of 2.8.

Reblog this post [with Zemanta]

Posted in Board of Directors, Chief executive officer, Department of Health and Human Services, Emergent BioSolutions Inc, Fuad, Fuad El-Hibri, Senior Vice President, Shareholders, U.S. Food and Drug Administration | No Responses »
Tags: , , , , , , , ,

Emergent BioSolutions Inc., Q2 2009 Earnings Call Transcript

Friday, August 14th, 2009

Emergent BioSolutions Inc., (EBS)

Q2 2009 Earnings Call

August 6, 2009 5:00 pm ET

Executives

Robert G. Burrows – Vice President, Investor Relations

Fuad El-Hibri – Chairman of the Board, Chief Executive Officer

R. Don Elsey – Chief Financial Officer

Daniel J. Abdun-Nabi – President, Chief Operating Officer

W. James Jackson, Ph.D. – Senior Vice President and Chief Scientific Officer

Analysts

Eric Schmidt – Cowen & Company

David Moskowitz – Caris & Company

Mona Ashiya – J.P. Morgan

Sean Long – Kennedy Capital Management

Presentation

Operator

Welcome to the Emergent BioSolutions Incorporated second quarter 2009 financial results conference call. (Operator Instructions) I would now like to turn the call over to Mr. Robert Burrows.

Robert Burrows

Good afternoon ladies and gentlemen. My name is Robert Burrows, Vice President of Investor Relations for Emergent. Thank you for joining us today as we discuss Emergent BioSolutions financial results for the second quarter and first six months of 2009. As is customary, our call today is open to all participants. In addition, the call is being recorded and is copyrighted by Emergent BioSolutions.

Joining me on the call this afternoon will be Fuad El-Hibri, Chairman and Chief Executive Officer, and Don Elsey, Chief Financial Officer. Additional members of our senior management team will be present on the call for purposes of the Q&A session.

Before we begin, however, I am compelled to remind everyone that during the all management may make projections and other forward-looking statements regarding future events and the company’s prospects or future performance. These forward-looking statements reflect Emergent’s current perspective on existing trends and information. Any such forward-looking statements are not guarantees of future performance and involve substantial risks and uncertainties. Actual results may differ materially from those projected in any forward-looking statements.

Reblog this post [with Zemanta]

Posted in BioThrax, Board of Directors, Chief executive officer, Department of Health and Human Services, Emergent BioSolutions Inc, Fuad, Fuad El-Hibri, Senior Vice President, Shareholders, U.S. Food and Drug Administration | No Responses »
Tags: , , , , , , , ,

Cornerstone Ceremony Welcomes New Vaccine Production Facility To Michigan

Monday, August 3rd, 2009

Emergent BioSolutions’ $75 Million Investment and Commitment to Michigan Applauded by Governor Granholm.

LANSING, MI, July 21, 2006 – Emergent BioSolutions, a biopharmaceutical company, announced today the dedication of a new large-scale vaccine production facility for its BioDefense Operations in a gala ceremony on itsLansing, Michigan campus. This $75 million dollar project represents a significant investment in the company’s future and adds biotechnology diversity to Michigan’s economy.

Governor Jennifer Granholm and other dignitaries and visitors, including Lansing Mayor Virgil Bernero and Major General Stephen Reeves (Executive Officer, Department of Defense Joint Program for Chemical and Biological Defense), were on hand for the cornerstone ceremony.
“This building represents a major investment in our biodefense business, and significantly expands our core manufacturing capabilities,” said Fuad El-Hibri, Chairman and Chief Executive Officer of Emergent BioSolutions. “When we purchased this facility from the state in 1998, we could only dream of being where we are today. With the support of our employees, our customers, the city of Lansing, and the state of Michigan, that dream is now a reality.”

The new 50,000-square-foot facility is designed to enable the company to expand production of its current product, BioThrax (Anthrax Vaccine Adsorbed), and will provide the potential opportunity for production of other products in the company’s pipeline. Construction of this facility began in February 2006 and is scheduled for completion in 2007. The company expects to initiate manufacturing in this new facility in 2008. BioThrax is the only FDA-approved anthrax vaccine. Present customers include the U.S. Department of Health and Human Services, the U.S. Department of Defense, and certain foreign governments.

“This historic Lansing site has seen a number of milestone events in its long history, and we’re proud to call Michigan home,” said Robert G. Kramer, President of BioDefense Operations for Emergent Solutions. “This project signifies our unwavering commitment to protecting life. This facility is designed to provide new and expanded capabilities to produce immunobiotics to defend against biological agents and other public health threats.”

About Emergent BioSolutions
Emergent BioSolutions is a biopharmaceutical company dedicated to protecting life through the development, manufacture, and commercialization of immunobioticsTM, which are novel products that direct the immune system to prevent and treat life-threatening diseases. These include products for prophylactic and therapeutic use against serious diseases where there exists significant unmet or underserved medical needs and against biological agents which may potentially be used as weapons of bioterrorism. The company currently employs more than 450 people with sites in Maryland, Michigan, the United Kingdom, Germany, and the Republic ofSingapore. More information about Emergent BioSolutions is available at www.emergentbiosolutions.com.

Reblog this post [with Zemanta]

Posted in Anthrax Therapeutic, BioThrax, Board of Directors, Chief executive officer, Department of Defense, Department of Health and Human Services, Emergent BioSolutions Inc, Fuad, Fuad El-Hibri, Michigan | No Responses »
Tags: , , , , , , ,

Fuad El-Hibri’s Linkedin Profile

Monday, August 3rd, 2009
Fuad El-Hibri is listed on Linkedin.com recently , Check the Directory page and click on profiles .
Fuad El-Hibri is currently Chairman and Chief Executive Officer at Emergent BioSolutions Inc.
http://www.emergentbiosolutions.com/images/hdsht_faud_el_hibri.jpg
Follow the directory link to know more about Fuad el-hibri

Posted in Chief executive officer, Emergent BioSolutions Inc, Ernst & Young Entrepreneur of the Year 2009, Fuad, Fuad El-Hibri, Linkedin | No Responses »
Tags: , , ,

Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young Entrepreneur of the Year 2009 Award Winner in Greater Washington

Monday, August 3rd, 2009

ROCKVILLE, Md.–(BUSINESS WIRE)–Emergent BioSolutions Inc. (NYSE:EBS – News) announced today that Fuad El-Hibri, its chairman and chief executive officer, received the Ernst & Young Entrepreneur of the Year® 2009 Award in the Technology category in Greater Washington. According to Ernst & Young LLP, the award recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses. Mr. El-Hibri was selected by an independent panel of judges and the award was presented at a special gala event on June 18 at the Ritz-Carlton, Tysons Corner in Virginia.

“It is a tremendous honor to receive this award considering the many biopharmaceutical and life sciences companies in the greater Washington region,” said Mr. El-Hibri. “I am proud of Emergent BioSolutions’ continuous growth and financial strength. These successes are firmly anchored on the entrepreneurial spirit and commitment of our employees. All their contributions, in pursuit of our company mission to protect life, have made this award possible.”

Under Mr. El-Hibri’s leadership, Emergent BioSolutions has expanded its capabilities in the development and manufacture of vaccines and immune-related therapeutics. By strengthening its core biodefense portfolio, which includes the only FDA-licensed vaccine against anthrax disease, Emergent has become the premier biodefense supplier of medical countermeasures to the U.S. government.

The Ernst & Young Entrepreneur of the Year awards program celebrates its 23rd anniversary this year and continues to honor entrepreneurs who have demonstrated excellence in such areas as innovation, financial performance, and personal commitment to their businesses and communities. The program has expanded to recognize business leaders in over 135 cities in 50 countries throughout the world.

As a Greater Washington award winner, Mr. El-Hibri is now eligible for consideration for the Ernst & Young Entrepreneur of the Year 2009 national program. Award winners in several national categories, as well as the overall national Ernst & Young Entrepreneur of the Year award winner, will be announced at the annual awards gala in Palm Springs, California on November 14, 2009. The awards are the culminating event of the Ernst & Young Strategic Growth Forum, the nation’s most prestigious gathering of high-growth, market-leading companies.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

About Ernst & Young’s Entrepreneur of the Year® Awards Program

Ernst & Young’s Entrepreneur of the Year® Award is the world’s most prestigious business award for entrepreneurs. The award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, the Ernst & Young Entrepreneur of the Year® award celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 135 cities in 50 countries.

Reblog this post [with Zemanta]

Posted in Anthrax Vaccine Adsorbed, Board of Directors, Chief executive officer, Emergent BioSolutions Inc, Ernst & Young Entrepreneur of the Year 2009, Fuad, Fuad El-Hibri | No Responses »
Tags: , , , , , , ,